Glypican 3型
肝细胞癌
医学
免疫疗法
癌症研究
免疫系统
生物标志物
抗体
免疫检查点
临床试验
细胞毒性
靶向治疗
癌症
免疫学
生物
内科学
体外
生物化学
作者
Takahiro Nishida,Hiroaki Kataoka
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2019-09-10
卷期号:11 (9): 1339-1339
被引量:139
标识
DOI:10.3390/cancers11091339
摘要
Glypican-3 (GPC3) is an oncofetal glycoprotein attached to the cell membrane by a glycophosphatidylinositol anchor. GPC3 is overexpressed in some kinds of tumors, particularly hepatocellular carcinoma (HCC). The prognostic significance of serum GPC3 levels and GPC3 immunoreactivity in tumor cells has been defined in patients with HCC. In addition to its usefulness as a biomarker, GPC3 has attracted attention as a novel therapeutic target molecule, and clinical trials targeting GPC3 are in progress. The major mechanism of anti-GPC3 antibody (GPC3Ab) against cancer cells is antibody-dependent cellular cytotoxicity and/or complement-dependent cytotoxicity. Since GPC3Ab is associated with immune responses, a combination of protocols with immune checkpoint inhibitors has also been investigated. Moreover, some innovative approaches for GPC3-targeting therapy have emerged in recent years. This review introduces the results of recent clinical trials targeting GPC3 in HCC and summarizes the latest knowledge regarding the role of GPC3 in HCC progression and clinical application targeting GPC3.
科研通智能强力驱动
Strongly Powered by AbleSci AI